Surgical Oncology
Volume 19, Issue 1 , Pages 38-45, March 2010

A meta-analysis of chemotherapy regimen Fluorouracil/Leucovorin/Oxaliplatin Compared with Fluorouracil/Leucovorin in treating advanced colorectal cancer

  • Mian Ling Chen

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 136 0001 0096; fax: +86 020 8104 5937.
    • ,
  • Chi Hua Fang

      Affiliations

    • Department of General Surgery, Zhu Jiang Hospital, Southern Medical University, Guang Zhou, Guang Dong 510282, PR China
    • ,
  • Liu Sen Liang

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China
    • ,
  • Li Hua Dai

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China
    • ,
  • Xiao Kang Wang

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China

Accepted 24 February 2009.

Abstract 

Background

We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer.

Methods

Two independent researchers identified and extracted all relevant literature using MEDLINE and the Cochrane Library Database. The regimens included arm A (FU/LV) and arm B (FU/LV/Oxaliplatin) with no other chemotherapy agent.

Results

Five randomized controlled trials (RCTs) fulfilled the requirements. All RCTs showed superiority of FU/LV/Oxaliplatin to FU/LV when measuring RR (response rate) and PFS (progression-free survival); no significant improvement in OS (overall survival) was observed. This meta-analysis shows a better RR for the FU/LV/Oxaliplatin group (OR 4.02, 95% CI 2.37–6.82, p<0.00001). The incidence of grade 3/4 toxicities, including neutropenia, thrombocytopenia, vomiting, neurological toxicity, toxicity-related dose modification and discontinuation was higher in the FU/LV/Oxaliplatin group, while the incidence of anemia, nausea and diarrhea was not different.

Conclusion

FU/LV/Oxaliplatin offers better efficacy (RR and PFS) than FU/LV in the treatment of advanced colorectal cancer. The incidence of grade 3/4 toxicities, i.e. neutropenia, thrombocytopenia, vomiting, neurological toxicity, is significantly higher in the FU/LV/Oxaliplatin than in the FU/LV group but these are manageable or reversible.

Keywords: Colorectal cancer, Chemotherapy, 5-Fluorouracil, Leucovorin, Oxaliplatin, Meta-analysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0960-7404(09)00037-1

doi:10.1016/j.suronc.2009.02.015

Surgical Oncology
Volume 19, Issue 1 , Pages 38-45, March 2010

Article Tools